文献速递外周动脉疾病

标准球囊血管成形术与Serranator锯齿球囊血管成形术治疗膝下动脉闭塞性疾病的比较:PRELUDE-BTK前瞻性研究的单中心亚组分析

Standard Balloon Angioplasty Versus Serranator Serration Balloon Angioplasty for the Treatment of Below-the-Knee Artery Occlusive Disease: A Single-Center Subanalysis From the PRELUDE-BTK Prospective Study.
PubMed 文献 · J Endovasc Ther · 2022-11-20

该单中心亚组分析比较了Serranator锯齿球囊与普通球囊(POBA)治疗膝下动脉病变的急性造影结果,Serranator组最终残余狭窄17.2%±8.2% vs POBA组33.7%±15.7%,平均管腔直径增益分别为1.64±0.41 mm和1.33±0.63 mm。Serranator组平均球囊扩张压力5 ATM低于POBA组的9 ATM,但Serranator组慢性完全闭塞(CTO)比例更高(41.2% vs 12%)。

要点

  • Serranator组最终残余狭窄17.2%±8.2%,低于POBA组的33.7%±15.7%。
  • Serranator组平均管腔直径增益1.64±0.41 mm,POBA组为1.33±0.63 mm。
  • Serranator组平均球囊扩张压力5 ATM,低于POBA组的9 ATM。

核心结论

  • 与标准球囊血管成形术相比,Serranator锯齿球囊为膝下动脉血管内治疗提供了一种新颖且有前景的作用机制,可能在复杂膝下动脉病变中起主导作用。

研究设计与样本

  • 本研究为PRELUDE-BTK多中心前瞻性核心实验室裁定研究的单中心亚组分析。
  • 本中心入组15例受试者并治疗17处病变,另单独分析25处POBA治疗的病变与Serranator亚组比较。
  • 两组病变均仅接受单纯球囊血管成形术或Serranator作为单独治疗,未使用药物洗脱等技术。
  • 急性造影结果由SynvaCor造影核心实验室分析,体积流量数据用流体流动模拟软件分析并与Poiseuille定律比较。

主要发现

  • 最终残余狭窄Serranator组为17.2%±8.2%,POBA组为33.7%±15.7%。
  • 平均管腔直径增益Serranator组为1.64±0.41 mm,POBA组为1.33±0.63 mm。
  • 平均大气球囊扩张压力Serranator组为5 ATM,POBA组为9 ATM。
  • 两组均未需要补救性支架,但Serranator组治疗的慢性完全闭塞(CTO)比例显著更高,为41.2% vs POBA组的12%。
  • 非CTO病变中,Serranator组治疗后与治疗前流量比值的计算平均值是POBA组的238%;CTO病例中Serranator组最终残余狭窄较POBA改善62%。

临床怎么用

  • 作者认为,对于晚期外周动脉疾病(PAD)和严重肢体缺血患者的膝下动脉复杂病变,Serranator装置可能有助于妥善解决常规技术面临的问题。
  • 作者认为,将Serranator球囊导管等现代技术整合到临床常规中是 mandatory 的,以在这些严重病变患者中获得更有利的结果,特别是降低死亡率和发病率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endovascular interventions in infrapopliteal occlusive artery disease are becoming more complex, and this frequently tests the standard method of treatment, plain old balloon angioplasty (POBA). The potential that serration angioplasty could produce a more acceptable tibial artery lumen was assessed in this study. AIM: The aim of this single-center subgroup analysis was to compare acute angiographic results after endovascular treatment using the Serranator serration balloon catheter in patients participating in the PRELUDE-BTK trial with POBA of the infrapopliteal arteries. A secondary objective was to assess post-treatment hemodynamic improvements. METHODS: Our center enrolled 15 subjects and treated 17 lesions within the multicenter prospective core laboratory-adjudicated PRELUDE-BTK study. A 25 lesions analyzed separately were treated with POBA and then compared with the Serranator subset. In both cohorts, lesions were treated with either plain angioplasty or Serranator as a stand-alone therapy; subsequent methods, such as drug elution technologies, were not used. Acute angiographic results were analyzed by the SynvaCor angiographic core laboratory. To assess volumetric flow rates, data were analyzed with a fluid flow simulation software and compared against Poiseuille's Law. RESULTS: Final residual stenosis was 17.2%±8.2% in the Serranator group versus 33.7%±15.7% in the POBA group. The mean lumen diameter (MLD) gain for the Serranator group and the POBA group was 1.64±0.41 mm and 1.33±0.63 mm, respectively. The average atmospheric balloon inflation pressure was 5 ATM in the Serranator group versus 9 ATM in the POBA group. Neither group required a bailout stent; however, it was notable that there were significantly more chronic total occlusions (CTOs) treated in the Serranator group at 41.2% versus 12% in the POBA group. Regarding the effectiveness in improving hemodynamic blood flow for non-CTO lesions, the calculated average ratio of post-treatment to pre-treatment flow rates in the Serranator group was 238% than that for the POBA group. For CTO cases where pre-treatment flow rate was zero, final residual stenosis was used as the parameter for comparison. The Serranator group showed a 62% improvement in final residual stenosis over POBA. CONCLUSION: Endovascular treatment of the infrapopliteal arteries by use of the Serranator serration balloon provides a novel and promising method of action compared with standard balloon angioplasty and, thus, may have a leading role in complex below-the-knee arterial lesions. CLINICAL IMPACT: The Serranator device might help to adequately address issues with conventional routine techniques for the treatment of complex lesions in infrapopliteal arteries in patients with advanced stages of PAD and critical limb ischemia. Integrating modern technologies such as the Serranator balloon catheter into clinical routine is mandatory in order to gain a more favorable outcome in these severely diseased patients and, particularly, to reduce mortality and morbidity.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Guetl K, Muster V, Schweiger L, et al. Standard Balloon Angioplasty Versus Serranator Serration Balloon Angioplasty for the Treatment of Below-the-Knee Artery Occlusive Disease: A Single-Center Subanalysis From the PRELUDE-BTK Prospective Study. J Endovasc Ther. 2022. PMID: 36408609. doi:10.1177/15266028221134891

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。